Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation

Molecular and Cellular Biology

Volumn 32, Issue 21, 2012, Pages 4283-4296

  Hrdliĉková, Radmila ^a   Nehyba, Jir̂í ^a   Bose, Henry R ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; WNT PROTEIN;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL TYPE; ENZYME ACTIVITY; EXON; GENE DELETION; GENE INSERTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TELOMERE;

EID: 84868674716     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00550-12     Document Type: Article

References (77)

1. Albritton LM, Tseng L, Scadden D, Cunningham JM. 1989. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane- spanning protein and confers susceptibility to virus infection. Cell 57: 659-666.
2. Amor S, et al. 2010. Alternative splicing and nonsense-mediated decay regulate telomerase reverse transcriptase (TERT) expression during virus- induced lymphomagenesis in vivo. BMC Cancer 10:571.
3. Atkinson SP, Hoare SF, Glasspool RM, Keith WN. 2005. Lack of telo- merase gene expression in alternative lengthening of telomere cells is as- sociated with chromatin remodeling of the hTR and hTERT gene promot- ers. Cancer Res. 65:7585-7590.
4. Avilion AA, et al. 1996. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 56:645-650.
5. Beck S, et al. 2011. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol. Cells 31:9-15.
6. Blackburn EH, Collins K. 2011. Telomerase: an RNP enzyme synthesizes DNA. Cold Spring Harb. Perspect. Biol. 3:a003558. doi:10.1101/ cshperspect.a003558.
7. Bodnar AG, et al. 1998. Extension of life-span by introduction of telo- merase into normal human cells. Science 279:349-352.
8. Bollmann FM. 2008. The many faces of telomerase: emerging extratelo- meric effects. Bioessays 30:728-732.
9. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. 1997. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3:1271-1274.
10. Casillas MA, Jr, Brotherton SL, Andrews LG, Ruppert JM, Tollefsbol TO. 2003. Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 316: 57-65.
11. Chang H, Delany ME. 2006. Complicated RNA splicing of chicken telo- merase reverse transcriptase revealed by profiling cells both positive and negative for telomerase activity. Gene 379:33-39.
12. Choi J, et al. 2008. TERT promotes epithelial proliferation through tran- scriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 4:e10. doi:10.1371/journal.pgen.0040010.
13. Colgin LM, et al. 2000. The hTERT Universal-GreekwithMathPi.-1.H9251 splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2:426-432.
14. Cong Y, Shay JW. 2008. Actions of human telomerase beyond telomeres. Cell Res. 18:725-732.
15. Counter CM, et al. 1998. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. U. S. A. 95:14723-14728.
16. Cristofalo VJ, Kritchevsky D. 1965. Growth and glycolysis in the human diploid cell strain WI-38. Proc. Soc. Exp. Biol. Med. 118:1109-1113.
17. Finkel T, Serrano M, Blasco MA. 2007. The common biology of cancer and ageing. Nat. Cell Biol. 448:767-774.
18. Flores I, Blasco MA. 2010. The role of telomeres and telomerase in stem cell aging. FEBS Lett. 584:3826-3830.
19. Geserick C, Blasco MA. 2006. Novel roles for telomerase in aging. Mech. Ageing Dev. 127:579-583.
20. González-Suárez E, et al. 2001. Increased epidermal tumors and in- creased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20:2619- 2630.
21. Goronzy JJ, Fujii H, Weyand CM. 2006. Telomeres, immune aging and autoimmunity. Exp. Gerontol. 41:246-251.
22. Greenberg RA, Allsopp RC, Chin L, Morin GB, DePinho RA. 1998. Expression of mouse telomerase reverse transcriptase during develop- ment, differentiation and proliferation. Oncogene 16:1723-1730.
23. Greider CW, Blackburn EH. 1985. Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell 43:405-413.
24. Greider CW, Blackburn EH. 1987. The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51:887-898.
25. Henson JD, Reddel RR. 2010. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett. 584:3800-3811.
26. Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK. 1998. The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology 248:295-304.
27. Hisatomi H, et al. 2003. Expression profile of a Universal-GreekwithMathPi.-1.H9253-deletion variant of the human telomerase reverse transcriptase gene. Neoplasia 5:193-197.
28. Hrdlicková R, Nehyba J, Bose HR, Jr. 2009. Regulation of telomerase activity by interferon regulatory factors 4 and 8 in immune cells. Mol. Cell. Biol. 29:929-941.
29. Hrdlicková R, Nehyba J, Humphries EH. 1994. In vivo evolution of c-rel oncogenic potential. J. Virol. 68:2371-2382.
30. Hrdlicková R, Nehyba J, Lim SL, Grützner F, Bose HR. 2012. Insights into the evolution of mammalian telomerase: platypus TERT shares sim- ilarities with genes of birds and other reptiles and localizes on sex chro- mosomes. BMC Genomics 13:216.
31. Hrdlicková R, Nehyba J, Liss AS, Bose HR, Jr. 2006. Mechanism of telomerase activation by v-Rel and its contribution to transformation. J. Virol. 80:281-295.
32. Jaskelioff M, et al. 2011. Telomerase reactivation reverses tissue degen- eration in aged telomerase-deficient mice. Nature 469:102-106.
33. Jaskelioff M, et al. 2009. Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. Oncogene 28:4225-4236.
34. Kilian A, et al. 1997. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6:2011-2019.
35. Kim NW, et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015.
36. Kim NW, Wu F. 1997. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 25:2595-2597.
37. Klein G, Dombos L, Gothoskar B. 1972. Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int. J. Cancer 10:44-57.
38. Lee J, et al. 2010. Telomerase deficiency affects normal brain functions in mice. Neurochem. Res. 35:211-218.
39. Lee J, et al. 2008. TERT promotes cellular and organismal survival inde- pendently of telomerase activity. Oncogene 27:3754-3760.
40. Lewis BP, Gree RE, Brenner SE. 2003. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay. Proc. Natl. Acad. Sci. U. S. A. 100:189-192.
41. Luco RF, et al. 2010. Regulation of alternative splicing by histone modi- fications. Science 327:996-1000.
42. Morgenstern JP, Land H. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18: 3587-3596.
43. Morrison LE, Boehmelt G, Enrietto PJ. 1992. Mutations in the rel- homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts. Oncogene 7:1137-1147.
44. Nehyba J, Hrdlicková R, Humphries EH. 1994. Evolution of the onco- genic potential of v-rel: rel-induced expression of immunoregulatory re- ceptors correlates with tumor development and in vitro transformation. J. Virol. 68:2039-2050.
45. Nilsen TW, Graveley BR. 2010. Expansion of the eukaryotic proteome by alternative splicing. Nature 463:457-463.
46. Nitta E, et al. 2011. Telomerase reverse transcriptase protects ATM- deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere independent mechanism. Blood 117:4169-4180.
47. O'Hare TH, Delany ME. 2011. Molecular and cellular evidence for the alternative lengthening of telomeres (ALT) mechanism in chicken. Cyto- genet. Genome Res. 135:65-78.
48. Osterhage JL, Friedman KL. 2009. Chromosome end maintenance by telomerase. J. Biol. Chem. 284:16061-16065.
49. Park JI, et al. 2009. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460:66-72.
50. Parkinson EK, Fitchett C, Cereser B. 2008. Dissecting the non-canonical functions of telomerase. Cytogenet. Genome Res. 122:273-280.
51. Prowse KR, Greider CW. 1995. Developmental and tissue-specific regu- lation of mouse telomerase and telomere length. Proc. Natl. Acad. Sci. U. S. A. 92:4818-4822.
52. Saebøe-Larssen S, Fossberg E, Gaudernack G. 2006. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA iso- forms from normal and tumour tissues. BMC Mol. Biol. 7:26.
53. Sahin E, DePinho RA. 2010. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 464:520-528.
54. Sanders RP, et al. 2004. Telomerase expression predicts unfavorable outcome in osteosarcoma. J. Clin. Oncol. 22:3790-3797.
55. Sarin KY, et al. 2005. Conditional telomerase induction causes prolifer- ation of hair follicle stem cells. Nature 436:1048-1052.
56. Schaefer-Klein J, et al. 1998. The EV-0-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virol- ogy 248:305-311.
57. Scherer WF, Syverton JT, Gey GO. 1953. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epider- moid carcinoma of the cervix. J. Exp. Med. 97:695-710.
58. Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer 33:787-791.
59. Shay JW, Wright WE. 2010. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett. 584:3819-3825.
60. Soengas MS, et al. 2001. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-211.
61. Steinert S, Shay JW, Wright WE. 2000. Transient expression of human telomerase extends the life span of normal human fibroblasts. Biochem. Biophys. Res. Commun. 273:1095-1098.
62. Stewart SA, et al. 2002. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. U. S. A. 99:12606-12611.
63. Sỳkorová E, Fajkus J. 2009. Structure-function relationships in telome- rase genes. Biol. Cell 101:375-392.
64. Taylor HA, Delany ME. 2000. Ontogeny of telomerase in chicken: impact of downregulation on pre- and postnatal telomere length in vivo. Dev. Growth Differ. 42:613-621.
65. Ulaner GA, Hu J-F, Vu TH, Giudice LC, Hoffman AR. 1998. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58:4168-4172.
66. Ulaner GA, Hu J-F, Vu TH, Giudice LC, Hoffman AR. 2001. Tissue- specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int. J. Cancer 91:644-649.
67. Ulaner GA, et al. 2000. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplas- tic ovary, endometrium and myometrium. Int. J. Cancer 85:330-335.
68. Ulaner GA, et al. 2003. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 63:1759-1763.
69. Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. 2003. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regu- lates gastrulation movements. Curr. Biol. 13:680-685.
70. Venkatesan RN, Price C. 1998. Telomerase expression in chickens: con- stitutive activity in somatic tissues and down-regulation in culture. Proc. Natl. Acad. Sci. U. S. A. 95:14763-14768.
71. von Zglinicki T. 2002. Oxidative stress shortens telomeres. Trends Biochem. Sci. 27:339-344.
72. Wang YL, et al. 2006. Immortalization of normal human cytotrophoblast cells by reconstitution of telomeric reverse transcriptase activity. Mol. Hum. Reprod. 12:451-460.
73. Wick M, Zubov D, Hagen G. 1999. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232:97-106.
74. Wojtyla A, Gladych M, Rubis B. 2011. Human telomerase activity reg- ulation. Mol. Biol. Rep. 38:3339-3349. doi:10.1007/s11033-010-0439-x.
75. Wyatt HDM, West SC, Beattie TL. 2010. InTERTpreting telomerase structure and function. Nucleic Acids Res. 38:5609-5622.
76. Xiang H, et al. 2002. Human telomerase accelerates growth of lens epi- thelial cells through regulation of the genes mediating RB/E2F pathway. Oncogene 21:3784-3791.
77. Yi X, et al. 2000. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2:433-440.